Catherinepan (Talk | contribs) (Blanked the page) |
|||
Line 1: | Line 1: | ||
+ | {{British_Columbia/Navbar}} | ||
+ | <html> | ||
+ | <head> | ||
+ | |||
+ | <meta charset="utf-8"> | ||
+ | <meta name="viewport" content="width=device-width, initial-scale=1"> | ||
+ | <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Josefin+Sans:300"> | ||
+ | |||
+ | <style> | ||
+ | |||
+ | h4{ | ||
+ | font-family: Josefin Sans; | ||
+ | color: #4a857e; | ||
+ | font-size: 25pt; | ||
+ | letter-spacing: -1px; | ||
+ | -webkit-text-stroke: 1px; | ||
+ | margin-left:100px; | ||
+ | margin-bottom:1px; | ||
+ | } | ||
+ | |||
+ | p { | ||
+ | font-family: Josefin Sans !important; | ||
+ | color: black; | ||
+ | font-size: 15pt !important; | ||
+ | letter-spacing: -1px; | ||
+ | margin-top: 10px; | ||
+ | margin-left: 110px !important; | ||
+ | line-height: 25px !important; | ||
+ | } | ||
+ | |||
+ | .row { | ||
+ | margin-bottom: 10px; | ||
+ | } | ||
+ | |||
+ | .wrapper { | ||
+ | display: flex; | ||
+ | width: 100%; | ||
+ | } | ||
+ | |||
+ | #in-content { | ||
+ | margin-left:20px; | ||
+ | max-width: 1000px; | ||
+ | } | ||
+ | |||
+ | html { | ||
+ | height: 100% !important; | ||
+ | } | ||
+ | |||
+ | |||
+ | </style> | ||
+ | |||
+ | </head> | ||
+ | <body> | ||
+ | |||
+ | <!-- page content --> | ||
+ | <div id="in-content"> | ||
+ | <div class="container"> | ||
+ | <div class = "row"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/4/40/T--British_Columbia--overview-hdg.png" style="height:28px; margin-top:35px;margin-left:100px;"> | ||
+ | </div> | ||
+ | <div class = "row"> | ||
+ | <p> Distributing metabolic pathways between microbial community members has shown significant potential for the large-scale production of complex, biologically-derived chemical products. Our goal is to address the challenge of regulating population dynamics in a synthetic microbial consortium, by improving the rate of production of naringenin and its pharmaceutically significant derivative, kaempferol, which has anti-cancer properties. This is done by distributing the synthesis of kaempferol between two E. coli strains and optimizing their relative proportions in co-culture. To optimize population dynamics for the production of kaempferol, we regulated the ratio of the two strains using GP2, a transcriptional inhibitor, under the control of a biosensor responsive to the pathway intermediate naringenin. This couples cell growth with the concentration of naringenin, allowing the co-culture to self-optimize based on pathway intermediate abundance. Using our system, we have demonstrated a novel way to optimize microbial polycultures for the synthesis of metabolically complex compounds. </p> |
Revision as of 00:39, 17 October 2018
Distributing metabolic pathways between microbial community members has shown significant potential for the large-scale production of complex, biologically-derived chemical products. Our goal is to address the challenge of regulating population dynamics in a synthetic microbial consortium, by improving the rate of production of naringenin and its pharmaceutically significant derivative, kaempferol, which has anti-cancer properties. This is done by distributing the synthesis of kaempferol between two E. coli strains and optimizing their relative proportions in co-culture. To optimize population dynamics for the production of kaempferol, we regulated the ratio of the two strains using GP2, a transcriptional inhibitor, under the control of a biosensor responsive to the pathway intermediate naringenin. This couples cell growth with the concentration of naringenin, allowing the co-culture to self-optimize based on pathway intermediate abundance. Using our system, we have demonstrated a novel way to optimize microbial polycultures for the synthesis of metabolically complex compounds.